Sabiedrība ar ierobežotu atbildību "Pharma Market"Active
Key figures
Ratios
2025Balance sheet structure
Dividends
calculatedNo dividends were paid.
Summary of financial statements2013–2025
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet — assets | |||||||||||||
| Total current assets | 205 069 | 327 192 | 309 209 | 321 747 | 331 336 | 331 402 | 287 935 | 185 939 | 138 376 | 155 659 | 167 805 | 170 747 | 185 027 |
| Total non-current assets | 4872 | 12 138 | 79 590 | 75 014 | 68 415 | 55 148 | 50 112 | 44 120 | 38 220 | 23 840 | 18 165 | 18 165 | 10 935 |
| Total assets | 209 941 | 339 330 | 388 799 | 396 761 | 399 751 | 386 550 | 338 047 | 230 059 | 176 596 | 179 499 | 185 970 | 188 912 | 195 962 |
| Balance sheet — liabilities and equity | |||||||||||||
| Current liabilities | 200 312 | 221 593 | 187 115 | 170 719 | 285 717 | 280 882 | 287 192 | 185 708 | 121 660 | 105 494 | 69 181 | 128 081 | 108 063 |
| Non-current liabilities | 219 | 4581 | 8532 | 2180 | 0 | 20 020 | 11 330 | 6650 | 2176 | 0 | 0 | 0 | 0 |
| Total liabilities | 200 531 | 226 174 | 195 647 | 172 899 | 285 717 | 300 902 | 298 522 | 192 358 | 123 836 | 105 494 | 69 181 | 128 081 | 108 063 |
| Share capital | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Retained earnings of previous periods | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Profit for the year | 6938 | 104 035 | 77 150 | 28 710 | -30 735 | -29 269 | 13 452 | 1369 | 15 059 | 21 245 | 42 784 | 4042 | 27 068 |
| Total equity | 8938 | 112 484 | 192 480 | 221 190 | 111 362 | 82 093 | 36 545 | 37 701 | 52 760 | 74 005 | 116 789 | 60 831 | 87 899 |
| Income statement | |||||||||||||
| Sales revenue | 283 679 | 778 241 | 918 696 | 1 016 586 | 1 527 143 | 1 313 699 | 850 232 | 599 953 | 476 096 | 646 171 | 786 935 | 793 818 | 883 692 |
| Operating profit | 8505 | 122 678 | 90 162 | 39 517 | -19 006 | -22 824 | 13 452 | 1369 | 15 059 | 21 245 | 42 784 | 19 380 | 27 068 |
| Profit before income tax | 8505 | 122 678 | 88 273 | 37 076 | -23 018 | -29 269 | 13 452 | 1369 | 15 059 | 21 245 | 42 784 | 19 380 | 27 068 |
| Profit for the reporting year | 6938 | 104 035 | 77 150 | 28 710 | -30 735 | -29 269 | 13 452 | 1369 | 15 059 | 21 245 | 42 784 | 4042 | 27 068 |
| Labour costs | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation of non-current assets | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other indicators | |||||||||||||
| Employees | 5 | 11 | 12 | 25 | 38 | 23 | 16 | 8 | 8 | 12 | 12 | 12 | 13 |
| Calculated dividend | 0 | 0 | 0 | 0 | 79 093 | 0 | 59 000 | 0 | 0 | 0 | 0 | 60 000 | 0 |
A dash (—) means the report has not been filed or the line is not reported; 0 is a zero stated in the report.
Connections graph
Click a node to see its other connections.
Related companies
Summary: Sabiedrība ar ierobežotu atbildību "Pharma Market"
Overview
Sabiedrība ar ierobežotu atbildību "Pharma Market" (reg. no. 41503064540) is a limited liability company. The company was registered in 2013 and has been in the register for 13 years. Registered address: Mārupes nov., Mārupe, Dzirnieku iela 24.
Financial results
Revenue in 2025 was 883 692 €, up 11,3% on the previous year (793 818 €). From 2013 to 2025, revenue grew by an average of 9,9% per year. Net profit for 2025 was 27 068 € (3,1% of revenue). The company was profitable in 11 of the 13 published years. In 2025 the company had 13 employees (12 a year earlier). Revenue per employee was 67 976 €. At the end of 2025, total assets were 195 962 € and equity 87 899 € (44,9% of assets).
Management and owners
The company has one board member. The sole owner of the company is a private individual.
Data sources and freshness
Register data (name, address, legal form, board and owners) and annual report figures come from the open data of the Register of Enterprises of the Republic of Latvia (CC0); entity.lv updates them daily. Data as of 03.11.2026. Changes, averages and ratios are calculated by entity.lv from open data and are not an official assessment.